Literature DB >> 8383939

Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.

F S Stals1, A Zeytinoglu, M Havenith, E de Clercq, C A Bruggeman.   

Abstract

Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), were evaluated for their effects on rat cytomegalovirus (RCMV)-induced interstitial pneumonitis after allogeneic bone marrow transplantation (BMTx). Eight-week-old Brown Norway rats immunosuppressed by a lethal dose of total body irradiation were inoculated with RCMV and received allogeneic bone marrow cells from Lewis rats. Animals were treated with either HPMPC (20 mg/kg of body weight as a single dose) or DHPG (20 mg/kg as two daily doses for 5 days). The effect of antiviral therapy was monitored by measuring RCMV titers in different organs and the histopathologic changes in lungs at 8 to 10 days postinfection. In RCMV-infected allogeneic BMTx recipients, severe diffuse thickening of alveolar septa (6.02 microns) with a diffuse infiltration of mononuclear cells occurred, whereas in the noninfected allogeneic BMTx recipients, the septal width was on the order of 2 microns (P < 0.01). Treatment with DHPG (20 mg/kg in two daily doses for 5 days) resulted in a decrease in virus titers (log10 PFU per gram of tissue) in lungs and spleens from 3.81 +/- 0.34 and 4.29 +/- 1.07 (untreated animals) to 1.26 +/- 0.53 and 3.22 +/- 0.27 (treated animals), respectively. Treatment with HPMPC (20 mg/kg as a single dose) resulted in a complete reduction of virus titers in all organs to below the detection level (P < 0.01). Furthermore, antiviral treatment resulted in a reduction of the alveolar septal width from 6.02 +/- 1.59 microns (untreated animals) to 4.67 +/- 1.70 and 3.32 +/- 0.63 microns after DHPG and HPMPC treatment, respectively. Treatment with HPMPC (20 mg/kg as a single dose) resulted in a complete reduction of virus titers in all organs to below the detection level (P <0.01). Furthermore, antiviral treatment resulted in a reduction of the alveolar septal width from 6.02 +/- 1.59 micrometre (untreated animals) to 4.67 +/- 0.63 micrometre after DHPG and HPMPC treatment, respectively. Furthermore, the influx of mononuclear cells in the alveolar septa was significantly impaired after treatment with HPMPC (P <0.01). We conclude that in the described rat model, HPMPC is highly effective in suppressing RCMV-induced interstitial pneumonitis after allogeneic BMTx.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383939      PMCID: PMC187642          DOI: 10.1128/AAC.37.2.218

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs.

Authors:  M J Reddehase; F Weiland; K Münch; S Jonjic; A Lüske; U H Koszinowski
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

2.  A novel selective broad-spectrum anti-DNA virus agent.

Authors:  E De Clercq; A Holý; I Rosenberg; T Sakuma; J Balzarini; P C Maudgal
Journal:  Nature       Date:  1986 Oct 2-8       Impact factor: 49.962

3.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

Authors:  E Engvall; P Perlmann
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

4.  Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis.

Authors:  J E Grundy; J D Shanley; G M Shearer
Journal:  Transplantation       Date:  1985-05       Impact factor: 4.939

5.  Passive transfer of cytomegalovirus by cardiac and renal organ transplants in a rat model.

Authors:  J H Bruning; C A Bruggeman; C P van Boven; P J van Breda Vriesman
Journal:  Transplantation       Date:  1986-06       Impact factor: 4.939

6.  Isolation of a cytomegalovirus-like agent from wild rats.

Authors:  C A Bruggeman; H Meijer; P H Dormans; W M Debie; G E Grauls; C P van Boven
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

7.  The pathogenesis of pneumonitis due to murine cytomegalovirus.

Authors:  J D Shanley; E L Pesanti; K M Nugent
Journal:  J Infect Dis       Date:  1982-09       Impact factor: 5.226

8.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.

Authors:  J Neyts; J Balzarini; L Naesens; E De Clercq
Journal:  J Med Virol       Date:  1992-05       Impact factor: 2.327

9.  Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia.

Authors:  D H Shepp; P S Dandliker; P de Miranda; T C Burnette; D M Cederberg; L E Kirk; J D Meyers
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

10.  Infection of laboratory rats with a new cytomegalo-like virus.

Authors:  C A Bruggeman; W M Debie; G Grauls; G Majoor; C P van Boven
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

View more
  1 in total

1.  Cellular distribution of CD200 receptor in rats and its interaction with cytomegalovirus e127 protein.

Authors:  Mohamed A El-Mokhtar; Agnieszka Bauer; Julia Madela; Sebastian Voigt
Journal:  Med Microbiol Immunol       Date:  2018-07-21       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.